PubRank

Do Your Genes Put You at a Higher Risk of Developing Mesothelioma

Clinical Trial ID NCT01590472

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01590472

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005 33.96
2 Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007 19.18
3 A common variant associated with prostate cancer in European and African populations. Nat Genet 2006 13.47
4 Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007 12.65
5 Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006 10.32
6 Advances in malignant mesothelioma. N Engl J Med 2005 8.50
7 Malignant mesothelioma. Lancet 2005 3.93
8 An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgüp in Anatolia. Thorax 1978 3.07
9 Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007 2.31
10 Changing patterns in asbestos-induced lung disease. Chest 2004 2.24
11 Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 1997 2.01
12 Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci U S A 2000 1.91
13 Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 1994 1.77
14 Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int J Cancer 1987 1.44
15 Effect of age at inoculation of asbestos on occurrence of mesotheliomas in rats. Int J Cancer 1976 1.27
16 Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010 1.23
17 Cardiovascular genomics, personalized medicine, and the National Heart, Lung, and Blood Institute: part I: the beginning of an era. Circ Cardiovasc Genet 2008 1.05
18 Malignant mesothelioma mortality--United States, 1999-2005. MMWR Morb Mortal Wkly Rep 2009 1.02
19 Genome-wide association studies: what do they teach us about asthma and chronic obstructive pulmonary disease? Proc Am Thorac Soc 2009 0.94
20 Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 2006 0.94
21 Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. Int J Cancer 2007 0.93
22 Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med 2010 0.92
23 Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci 1991 0.91
24 Lung structure as a risk factor in adverse pulmonary responses to asbestos exposure. A case-referent study in Quebec chrysotile miners and millers. Am Rev Respir Dis 1983 0.91
25 Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene 2010 0.89
26 Asbestosis: clinical spectrum and pathogenic mechanisms. Proc Soc Exp Biol Med 1997 0.89
27 Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study. Mutat Res 2006 0.86
28 Identification of a mesothelioma phenotype. Respir Med 2006 0.84
29 Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2005 0.84
30 Descriptive epidemiology of malignant mesothelioma. Med Lav 2006 0.83
31 Integrin alpha-2 and beta-3 gene polymorphisms and colorectal cancer risk. Int J Colorectal Dis 2008 0.82
32 Asbestos induction of extended lifespan in normal human mesothelial cells: interindividual susceptibility and SV40 T antigen. Carcinogenesis 1999 0.81
33 Osteopontin modulates malignant pleural mesothelioma cell functions in vitro. Anticancer Res 2009 0.80
34 Women and mesothelioma. Chest 2002 0.77
35 Preoperative assessment and therapeutic options for patients with malignant pleural mesothelioma. Thorac Surg Clin 2004 0.75
Next 100